PRMT5 Inhibitor Compounds Balancing Selectivity and Potency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
PRMT5 is aberrantly expressed in various human cancers and plays a role in epigenetic changes leading to poor prognosis, and is also involved in the silencing of fetal globin genes, making it a target for therapeutic intervention in hemoglobinopathies like β-thalassemia and sickle cell disease.
Innovation Solution
Development of compounds that inhibit the activity of PRMT5, offering potential therapeutic benefits in treating cancer and hemoglobinopathies by targeting PRMT5 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule inhibitors are used to target PRMT5, then selectivity and oral bioavailability improve, but achieving sufficient potency and cellular activity becomes difficult
Solution Approach 1:
The patent employs parameter changes by modifying molecular weight parameters (ranging from 200-500 Da), hydrophobicity parameters (logP values), and structural parameters (ring structures, heteroatoms) to optimize the balance between selectivity and potency. Specific compounds with defined molecular weights and structural features are designed to achieve both oral bioavailability and sufficient cellular activity.
Solution Approach 2:
The patent applies local quality by introducing specific functional groups and structural motifs at particular positions within the small molecule structure. Heteroatoms, ring structures, and substituent groups are strategically placed to enhance binding affinity and selectivity for PRMT5 while maintaining appropriate pharmacokinetic properties.
2Reliability
If PRMT5 is inhibited to treat cancer, then tumor growth suppression improves, but off-target effects and toxicity may increase
Solution Approach 1:
The patent applies segmentation by dividing the PRMT5 enzyme structure into specific binding pockets and recognizing distinct substrate recognition elements. Inhibitors are designed to target specific regions of PRMT5 with high precision, reducing off-target effects on other protein arginine methyltransferases or cellular components.
Solution Approach 2:
The patent uses intermediary mechanisms by designing compounds that specifically recognize and bind to unique features of PRMT5's active site or substrate binding region. The inhibitors act as selective mediators that distinguish PRMT5 from other enzymes through specific molecular interactions, thereby minimizing off-target effects while maintaining antitumor activity.
3Manufacturing precision
If complex macromolecular inhibitors are used against PRMT5, then potency improves, but cell permeability and oral bioavailability deteriorate
Solution Approach 1:
The patent systematically changes molecular size parameters, maintaining compounds within a specific molecular weight range (200-500 Da) that balances potency with cell permeability. Hydrophobicity parameters are optimized through controlled logP values, and structural complexity is limited to ensure adequate membrane penetration while retaining sufficient binding affinity.
Solution Approach 2:
The patent applies dynamics by designing flexible small molecule structures that can adapt to the PRMT5 binding site while maintaining appropriate pharmacokinetic properties. The molecules possess dynamic conformational flexibility that allows them to penetrate cell membranes effectively while achieving high potency through induced fit binding mechanisms.
Data Source
AI summary
The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.